People: Alere Inc (ALR)

ALR on New York Consolidated

37.55USD
24 Oct 2014
Price Change (% chg)

$-0.31 (-0.82%)
Prev Close
$37.86
Open
$38.00
Day's High
$38.00
Day's Low
$37.07
Volume
329,066
Avg. Vol
702,332
52-wk High
$43.00
52-wk Low
$30.93

Search Stocks

Eylenbosch, Hilde 

Brief Biography

Dr. Hilde Eylenbosch, M.D., is President, Alere International Limited of Alere, Inc. Prior to that she held the title of President, Europe and Middle East since February 2012. Previously, Dr. Eylenbosch served as Chief Commercial Officer from November 2010 to February 2012, after having served as our Senior Vice President, Marketing from July 2010 to November 2010 and as our Vice President, Marketing from April 2009 to July 2010. She served as Chief Executive Officer of SPD Swiss Precision Diagnostics GmbH, our 50/50 joint venture with Procter & Gamble, from its inception in May 2007 until April 2009. Dr. Eylenbosch has also served as our President, Consumer Diagnostics since June 2006. Prior to assuming that title she served as Vice President, Consumer Diagnostics from July 2005 to June 2006, Vice President, Consumer Marketing from October 2004 to July 2005 and Vice President of International Women’s Health from November 2001 to October 2004. Dr. Eylenbosch served in the same capacity for our predecessor company, Inverness Medical Technology, from August 2001 until that company was acquired by Johnson & Johnson in November 2001. Prior to that, she held various positions at Inverness Medical Technology, including Director of U.S. Women’s Health from September 1998 through October 2000. When she joined Inverness Medical Technology in January 1995, Dr. Eylenbosch was responsible for marketing that company’s women’s health products in Europe. Before joining Inverness Medical Technology, Dr. Eylenbosch was employed by Synthelabo, a French pharmaceutical company, where she held various marketing positions.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
559,676 -- 511,800 1,071,480

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 45,765 634,318.00
Name Fiscal Year Total

Namal Nawana

1,307,790

David Teitel

540,779

Daniella Cramp

--

Hilde Eylenbosch

1,071,480

Craig Keyes

--

Sanjay Malkani

--
As Of 30 Dec 2013
Search Stocks